Cover Image

Update on treatment of polymyalgia rheumatica

D. Camellino, C. Dejaco
  • C. Dejaco
    Service of Rheumatology, ASL dell’Alto Adige, Hospital of Brunico, Brunico (BZ), Italy; Department of Rheumatology, University of Medicine of Graz, Graz, Austria


Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease in the elderly after rheumatoid arthritis. It is clinically characterised by pain and stiffness in the neck, proximal shoulder and hip girdle. Glucocorticoids (GCs) are the cornerstone of PMR treatment, but they are associated with potentially severe side effects. Among GC-sparing agents, methotrexate revealed a modest benefit in clinical trials, and recently, there have been promising reports from tocilizumab. In this review, we summarize the available evidence on the treatment of PMR and the possible role in the future of other agents under investigation.


Polymyalgia rheumatica; large vessel vasculitis; glucocorticoids; disease modifying anti-rheumatic drugs; biologics.

Full Text:

Submitted: 2017-08-17 16:12:16
Published: 2018-03-27 17:38:45
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2018 D. Camellino, C. Dejaco

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy